Protagonist Therapeutics PTGX Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's proceeds from exercises of stock options and other stock issuances?
- Protagonist Therapeutics (PTGX) reported proceeds from exercises of stock options and other stock issuances of $23.37M in Q1 2026.
- How has Protagonist Therapeutics's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Protagonist Therapeutics's proceeds from exercises of stock options and other stock issuances increased by 96.1% year-over-year, from $11.92M to $23.37M.
- What is the long-term trend for Protagonist Therapeutics's proceeds from exercises of stock options and other stock issuances?
- Over 4 years (2021 to 2025), Protagonist Therapeutics's proceeds from exercises of stock options and other stock issuances has grown at a 38.8% compound annual growth rate (CAGR), from $6.28M to $23.34M.